Adam X. Miranda

Adam X. Miranda

Auto-generated profile, based on publicly available information

Adam X. Miranda

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HWHong Yuen Wong
Hong Yuen Wong
QSQuanhu Sheng
Quanhu Sheng
AHAmanda B. Hesterberg
Amanda B. Hesterberg
SCSarah Croessmann
Sarah Croessmann
BRBrenda L. Rios
Brenda L. Rios
PHPaula J Hurley
Paula J Hurley
Cribriform prostate cancer, found in both invasive cribriform carcinoma (ICC) and intraductal carcinoma (IDC), is an aggressive histological subtype that is associated with progression to lethal disease. To delineate the molecular and cellular underpinnings of ICC/IDC aggressiveness, this study examines paired ICC/IDC and benign prostate surgical samples by single-cell RNA-sequencing, TCR sequencing, and histology. ICC/IDC cancer cells express genes associated with metastasis and targets with potential for therapeutic intervention. Pathway analyses and ligand/receptor status model cellular interactions among ICC/IDC and the tumor microenvironment (TME) including JAG1/NOTCH. The ICC/IDC TME is hallmarked by increased angiogenesis and immunosuppressive fibroblasts (CTHRC1+ASPN+FAP+ENG+) along with fewer T cells, elevated T cell dysfunction, and increased C1QB+TREM2+APOE+-M2 macrophages. These findings support that cancer cell intrinsic pathways and a complex immunosuppressive TME contribute to the aggressive phenotype of ICC/IDC. These data highlight potential therapeutic opportunities to restore immune signaling in patients with ICC/IDC that may afford better outcomes.

10 April 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
WJWendy N Jefferson
Wendy N Jefferson
HKH Karimi Kinyamu
H Karimi Kinyamu
TWTianyuan Wang
Tianyuan Wang
AMAdam X Miranda
Adam X Miranda
EPElizabeth Padilla-Banks
Elizabeth Padilla-Banks
CWCarmen J Williams
Carmen J Williams
Little is known regarding how steroid hormone exposures impact the epigenetic landscape in a living organism. Here, we took a global approach to understanding how exposure to the estrogenic chemical, diethylstilbestrol (DES), affects the neonatal mouse uterine epigenome. Integration of RNA- and ChIP-sequencing data demonstrated that ∼80% of DES-altered genes had higher H3K4me1/H3K27ac signal in close proximity. Active enhancers, of which ∼3% were super-enhancers, had a high density of estrogen receptor alpha (ERα) binding sites and were correlated with alterations in nearby gene expression. Conditional uterine deletion of ERα, but not the pioneer transcription factors FOXA2 or FOXO1, prevented the majority of DES-mediated changes in gene expression and H3K27ac signal at target enhancers. An ERα dependent super-enhancer was located at the Padi gene locus and a topological connection to the Padi1 TSS was documented using 3C-PCR. Chromosome looping at this site was independent of ERα and DES exposure, indicating that the interaction is established prior to ligand signaling. However, enrichment of H3K27ac and transcriptional activation at this locus was both DES and ERα-dependent. These data suggest that DES alters uterine development and consequently adult reproductive function by modifying the enhancer landscape at ERα binding sites near estrogen-regulated genes.

22 December 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
JAJuan Pablo Arroyo
Juan Pablo Arroyo
ATAndrew S. Terker
Andrew S. Terker
YZYvonne Zuchowski
Yvonne Zuchowski
JWJason A. Watts
Jason A. Watts
FBFabian Bock
Fabian Bock
RHRaymond C Harris
Raymond C Harris
Vasopressin has traditionally been thought to be produced by the neurohypophyseal system and then released into the circulation where it regulates water homeostasis. The questions of whether vasopressin could be produced outside of the brain and if the kidney could be a source of vasopressin are raised by the syndrome of inappropriate antidiuretic hormone secretion (vasopressin). We found that mouse and human kidneys expressed vasopressin mRNA. Using an antibody that detects preprovasopressin, we found that immunoreactive preprovasopressin protein was found in mouse and human kidneys. Moreover, we found that murine collecting duct cells made biologically active vasopressin, which increased in response to NaCl-mediated hypertonicity, and that water restriction increased the abundance of kidney-derived vasopressin mRNA and protein expression in mouse kidneys. Thus, we provide evidence of biologically active production of kidney-derived vasopressin in kidney tubular epithelial cells.

Verified
Journal Article
Open access
PDF file
DWDemond Williams
Demond Williams
EHEbony Hargrove-Wiley
Ebony Hargrove-Wiley
WBWendy Bindeman
Wendy Bindeman
DVDaniel Valent
Daniel Valent
AMAdam X. Miranda
Adam X. Miranda
BFBarbara Fingleton
Barbara Fingleton
Interleukin-4 (IL4) is a Th2 cytokine that can signal through two different receptors, one of which—the type II receptor—is overexpressed by various cancer cells. Previously, we have shown that type II IL4 receptor signaling increases proliferation and metastasis in mouse models of breast cancer, as well as increasing glucose and glutamine metabolism. Here, we expand on those findings to determine mechanistically how IL4 signaling links glucose metabolism and histone acetylation to drive proliferation in the context of triple-negative breast cancer (TNBC). We used a combination of cellular, biochemical, and genomics approaches to interrogate TNBC cell lines, which represent a cancer type where high expression of the type II IL4 receptor is linked to reduced survival. Our results indicate that type II IL4 receptor activation leads to increased glucose uptake, Akt and ACLY activation, and histone acetylation in TNBC cell lines. Inhibition of glucose uptake through the deletion of Glut1 ablates IL4-induced proliferation. Additionally, pharmacological inhibition of histone acetyltransferase P300 attenuates IL4-mediated gene expression and proliferation in vitro. Our work elucidates a role for type II IL4 receptor signaling in promoting TNBC progression, and highlights type II IL4 signaling, as well as histone acetylation, as possible targets for therapy.

7 October 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RBRiley E. Bergman
Riley E. Bergman
CKChristin I. Keeton
Christin I. Keeton
ISIrika R. Sinha
Irika R. Sinha
JLJonathan P. Ling
Jonathan P. Ling
YWYu Wang
Yu Wang
BPBen H. Park
Ben H. Park
Tumor genomic profiling has uncovered many cancer drivers whose implications in terms of tumor biology and therapeutic actionability remain understudied. Hotspot mutations in SF3B1 induce widespread transcriptomic alterations and occur across multiple cancer types. Despite this, the biological and clinical consequences of SF3B1 mutations remain elusive. Characterization of the largest SF3B1 mutant breast cancer clinical cohort to date identifies SF3B1 driver mutations in approximately 2.5% of HR+ HER2- breast cancer, with strong enrichment of K700E substitutions, substantial variation in variant allele fraction (VAF), and significantly improved overall survival due to enrichment in Luminal A disease. In vitro and in vivo studies in representative cell models suggest several of the most prevalent SF3B1 mutations have deleterious effects on cell growth, leading to selective loss of the mutation over time, providing a rationale for the low frequency and low VAF of SF3B1 mutations in breast cancer. Though all introduced hotspot mutations limit growth and are reverted to wildtype (WT) over time, mutations at position R625 have a more pronounced phenotype than K700E, providing an explanation for the clinically observed skew in mutation frequencies. RNA and DNA sequencing analyses were used to identify characteristic pathway-level transcriptomic changes in SF3B1 -mutant cells and identify copy number alterations as a mechanism of both improved mutation tolerability and a means to eliminate the mutation over time. These data suggest that while SF3B1 mutations are enriched in some clinical contexts, their role in breast tumorigenesis is highly complex and dependent on secondary events that overcome their deleterious effects on cell growth and survival.

12 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
VMVerda Miranda
Verda Miranda
TSTimothy J. Scott
Timothy J. Scott
EDElizabeth Dorans
Elizabeth Dorans
SMShaojun Mei
Shaojun Mei
AMAdam X. Miranda
Adam X. Miranda
EHEmily Hodges
Emily Hodges
Genome-wide association studies (GWAS) have identified hundreds of genetic loci linked to pancreatic islet dysfunction and type 2 diabetes (T2D). Many of these loci map to islet genes and their enhancers; however, a complete understanding of the gene regulatory contributions to T2D is lacking. We have previously shown that cell-type specific DNA hypomethylation patterns identify gene enhancers that contribute to the heritability of cell-type relevant traits. Here, we determine a reference dataset of islet hypomethylated regions (HMRs) from DNA methylomes of donors without T2D. Comparing islet HMRs to profiles from functionally diverse cell types, we identify ∼4,800 islet-specific HMRs and demonstrate their enrichment for key genes and transcription factor motifs essential for β cell function. We further show that islet-specific HMRs are highly enriched for GWAS variants that contribute specifically to T2D heritability. Leveraging genotype-phenotype data from the Vanderbilt BioVU biobank, which links patient DNA to electronic health records (EHR), we perform phenome- and lab-wide association scans that replicate islet HMR associations with T2D and uncover novel links to related clinical traits. To overcome challenges posed by stringent GWAS significance thresholds, we develop an HMR-WAS, which allows detection of T2D signals in our smaller BioVU cohort. Our comprehensive framework reveals enhancers of genes involved in insulin secretion and glucose metabolism and demonstrates the impact of T2D-associated variants on their transcriptional activity. By integrating HMRs with patient EHR, our work underscores the potential to reveal new enhancer loci associated with disease risk, especially those missed in a conventional GWAS.